IPK’s first-in-class TB drug candidate is licensed out by Qurient to TB Alliance for further development starting Phase2b 

We are excited to share the good news in the battle to combat tuberculosis (TB). Q203 (Telacebec), the first-in-class drug candidate for MDR- & XDR-TB identified by Insitut Pasteur Korea’s(IPK), was licensed by Qurient Co. Ltd to TB Alliance*, a global institution dedicated to ending TB.
The Telacebec is expected to strengthen ongoing global efforts in the fight against tuberculosis, as the TB Alliance intends to proceed quickly with further development starting from phase 2b of clinical trials.

Telacebec has a novel mechanism of action that inhibits Mycobacterium tuberculosis growth by targeting the respiratory cytochrome bc1 complex, thus can be effective against MDR- and XDR-TB.
IPK researchers discovered this drug candidate by integrating a physiologically relevant cellular disease model, image-based screening and medicinal chemistry technology, and published the results in Nature Medicine in 2013**.
Q203 was licensed to Qurient Co. Ltd., a spin-off bio venture company of Institut Pasteur Korea. Qurient Co. Ltd. named Q203 Telacebec and successfully conducted research from preclinical to Phase 2a studies. In particular, clinical Phase 2a results were published in the New England Journal of Medicine*** and the superiority of Telacebec became widely known around the world.